Appendix 4E - Preliminary Final Report 2016/17
30 August 2017 CLINUVEL PHARMACEUTICALS LTD is a global biopharmaceutical company focused...
Read More
Notice of change of interests of a substantial holder
09 August 2017 Enclosed is a notice of a change of interests...
Read More
Appendix 4C - Quarterly report
31 July 2017 The Appendix 4C lodged earlier today reported in item...
Read More
CLINUVEL Newsletter - July 2017
10 July 2017 For those who have followed the Company over the...
Read More
Appendix 3B
10 May 2017 enclosed is a new issue announcement, application for quotation...
Read More
CLINUVEL Newsletter - May 2017
10 May 2017 I look back at a turbulent period, as CLINUVEL...
Read More
NICE ENGLAND UPDATE ON SCENESSE®
2 May 2017 CLINUVEL PHARMACEUTICALS LIMITED today announced that the Department of...
Read More
Appendix 4C - Quarterly report
28 April 2017 CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL...
Read More
Lapse and Forfeit of Unlisted Conditional Performance Rights
12 April 2017 CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL...
Read More
CLINUVEL reaches agreement on German SCENESSE® pricing through AMNOG Arbitration Board
12 April 2017 CLINUVEL today announced that it had reached agreement with...
Read More
Appendix 4D and Half Year Report
24 February 2017 Your Directors present their report on the Company and...
Read More
CLINUVEL Newsletter - February 2017
16 February 2017 I wish all stakeholders of the CLINUVEL Group a...
Read More